Atria Wealth Solutions Inc. Cuts Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Atria Wealth Solutions Inc. lessened its stake in DexCom, Inc. (NASDAQ:DXCM) by 2.9% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,819 shares of the medical device company’s stock after selling 142 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in DexCom were worth $545,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in DXCM. Avalon Trust Co purchased a new stake in DexCom in the 1st quarter worth $26,000. Whittier Trust Co. boosted its stake in DexCom by 684.4% during the 1st quarter. Whittier Trust Co. now owns 251 shares of the medical device company’s stock worth $29,000 after purchasing an additional 219 shares during the last quarter. Atlas Capital Advisors LLC acquired a new stake in DexCom during the 2nd quarter worth $33,000. CoreCap Advisors LLC acquired a new stake in DexCom during the 4th quarter worth $35,000. Finally, TFC Financial Management Inc. boosted its stake in DexCom by 4,814.3% during the 1st quarter. TFC Financial Management Inc. now owns 344 shares of the medical device company’s stock worth $40,000 after purchasing an additional 337 shares during the last quarter. Hedge funds and other institutional investors own 93.88% of the company’s stock.

DexCom Trading Down 5.1 %

NASDAQ DXCM opened at $96.35 on Monday. The firm’s 50-day moving average is $115.60 and its two-hundred day moving average is $118.29. DexCom, Inc. has a 12 month low of $78.94 and a 12 month high of $139.55. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.42 and a quick ratio of 2.21. The stock has a market capitalization of $37.37 billion, a P/E ratio of 112.03, a PEG ratio of 1.99 and a beta of 1.12.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, July 27th. The medical device company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.12. DexCom had a net margin of 11.18% and a return on equity of 22.01%. The company had revenue of $871.30 million for the quarter, compared to analysts’ expectations of $841.16 million. During the same quarter in the prior year, the company posted $0.17 earnings per share. DexCom’s revenue for the quarter was up 25.2% compared to the same quarter last year. On average, sell-side analysts anticipate that DexCom, Inc. will post 1.23 earnings per share for the current year.

Insiders Place Their Bets

In other DexCom news, Director Bridgette P. Heller sold 600 shares of the business’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $106.56, for a total transaction of $63,936.00. Following the sale, the director now directly owns 23,731 shares in the company, valued at $2,528,775.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other DexCom news, Director Steven Robert Pacelli sold 411 shares of the business’s stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $107.03, for a total transaction of $43,989.33. Following the sale, the director now directly owns 126,008 shares in the company, valued at $13,486,636.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bridgette P. Heller sold 600 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $106.56, for a total transaction of $63,936.00. Following the sale, the director now owns 23,731 shares in the company, valued at $2,528,775.36. The disclosure for this sale can be found here. Insiders have sold 9,550 shares of company stock worth $1,189,620 over the last three months. Company insiders own 0.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on DXCM shares. Citigroup lifted their target price on shares of DexCom from $146.00 to $150.00 in a research note on Monday, July 10th. StockNews.com started coverage on shares of DexCom in a research note on Thursday, August 17th. They set a “hold” rating on the stock. Raymond James lowered their target price on shares of DexCom from $154.00 to $131.00 and set a “strong-buy” rating on the stock in a research note on Friday. Morgan Stanley began coverage on shares of DexCom in a research report on Tuesday, May 30th. They set an “equal weight” rating and a $131.00 price target on the stock. Finally, Canaccord Genuity Group boosted their price target on shares of DexCom from $135.00 to $150.00 and gave the company a “buy” rating in a research report on Friday, July 28th. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, DexCom currently has an average rating of “Moderate Buy” and a consensus target price of $136.31.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices for specific and permitted use cases, including non-medical device applications, medical device data analysis, integrated continuous glucose monitoring systems (iCGM) secondary display alarms, active patient monitoring, and treatment decisions; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.